Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronocort vs immediate-release hydrocortisone in congenital adrenal hyperplasia (Japan)
jRCT2031210491Phase 3Completed
- Sponsor
- Diurnal Group plc
- Start
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of hydrocortisone modified-release in 21-hydroxylase deficiency (21-OHD) (2 arms), sponsored by Diurnal Group plc. Primary endpoint: Biochemical responder rate at 28 weeks. Started May 2022; status: completed.
02
Drugs
hydrocortisone modified-release
03
Conditions
21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on jRCT2031210491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210491.